SEARCH

SEARCH BY CITATION

References

  • Ashall F. and Goate A. M. (1994) Role of the beta-amyloid precursor protein in Alzheimer’s disease. Trends Biochem. Sci. 19, 4246.
  • Busche M. A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K. H., Haass C., Staufenbiel M., Konnerth A. and Garaschuk O. (2008) Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science 321, 16861689.
  • Cai X. D., Golde T. E. and Younkin S. G. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514516.
  • Castellano J. M., Kim J., Stewart F. R. et al. (2011) Human apoE isoforms differentially regulate brain amyloid-{beta} peptide clearance. Sci. Transl. Med. 3, 89ra57.
  • Chartier-Harlin M. C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Hardy J. and Mullan M. (1991) Early onset Alzheimer’s disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844846.
  • Check Hayden E. (2011) Patent dispute threatens US Alzheimer’s research. Nature 472, 2020; Published online doi: 10.1038/472020a.
  • Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. and Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzhcimcr’s discase causes increased beta-amyloid production. Nature 360, 672674.
  • Clark R. F., Hutton M., Fuldner R. A. et al. (1995) The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat. Genet. 11, 219222.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921923.
  • Corder E. H., Saunders A. M., Risch N. J. et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180184.
  • Craig-Schapiro R., Perrin R. J., Roe C. M. et al. (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol. Psychiatry 68, 903912.
  • De Strooper B. (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465494.
  • Delabar J. M., Goldgaber D., Lamour Y., Nicole A., Huret J. L., De Grouchy J., Brown P., Gajdusek D. C. and Sinet P. M. (1987) Beta amyloid gene duplication in Alzheimer’s disease and karyotypically normal Down syndrome. Science 235, 13901392.
  • van Duinen S. G., Castaño E. M., Prelli F., Bots G. T., Luyendijk W. and Frangione B. (1987) Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc. Natl. Acad. Sci. USA 84, 59915994.
  • Fagan A. M., Roe C. M., Xiong C., Mintun M. A., Morris J. C. and Holtzman D. M. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343349.
  • Frautschy S. A., Yang F., Irrizarry M., Hyman B., Saido T. C., Hsiao K. and Cole G. M. (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152, 307317.
  • Games D., Adams D., Alessandrini R. et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature 373, 523527.
  • Glenner G. G. and Wong C. W. (1984a) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890.
  • Glenner G. G. and Wong C. W. (1984b) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 11311135.
  • Goate A. (2006) Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer’s disease. J. Alzheimers Dis. 9(3 Suppl.) 341347.
  • Goate A. M., Haynes A. R., Owen M. J. et al. (1989) Predisposing locus for Alzheimer’s disease on chromosome 21. Lancet 1, 352355.
  • Goate A. M., Chartier-Harlin M. C., Mullan M. C. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704706.
  • Golde T. E., Schneider L. S. and Koo E. H. (2010) Anti Aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 69, 203213.
  • Goldgaber D., Lerman M. I., McBride W. O., Saffiotti U. and Gajdusek D. C. (1987) Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer’s disease, Down’s syndrome and aging. J. Neural Transm. Suppl. 24, 2328.
  • Haass C., Schlossmacher M. G., Hung A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 359, 322325.
  • Hardy J. and Allsop D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharm. Sci. 12, 383388.
  • Hardy J. A. and Higgins G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 286, 184185.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hardy J., Duff K., Hardy K. G., Perez-Tur J. and Hutton M. (1998) Genetic dissection of Alzheimer’s disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1, 355358.
  • Harold D., Abraham R., Hollingworth P. et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet. 41, 10881093.
  • Herzig M. C., Winkler D. T., Burgermeister P. et al. (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954960.
  • Hollingworth P., Harold D., Sims R. et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 43, 429435.
  • Holmes C., Boche D., Wilkinson D. et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216223.
  • Holtzman D., Morris J. C. and Goate A. M. (2011) Alzheimer’s disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr1.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274, 99102.
  • Hutton M., Lendon C. L., Rizzu P. et al. Coding and splice donor site mutations in tau cause autosomal dominant dementia (FTDP-17). Nature (1998) 393, 702705
  • Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D. and Hyman B. T. (1997) Aß deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 70537059.
  • Jack. C. R., Jr, Wiste H. J., Vemuri P. et al. (2010) Alzheimer’s Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 133, 33363348.
  • Jones L., Holmans P. A., Hamshere M. L. et al. (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s Disease. PLoS ONE 5, e13950.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Müller-Hill B. (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., Van Duinen S. G., Bots G. T., Luyendijk W. and Frangione B. (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 11241126.
  • Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 14871491.
  • Li G., Sokal I., Quinn J. F. et al. (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69, 631639.
  • Masliah E., Sisk A., Mallory M., Mucke L., Schenk D. and Games D. (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F ß-amyloid precursor protein and Alzheimer’s disease. J. Neurosci. 16, 57955811.
  • Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E. and Bateman R. J. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330, 1774.
  • Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B. and Lannfelt L. (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1, 345347.
  • Murrell J., Farlow M., Ghetti B. and Benson M. D. (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254, 9799.
  • Naj A. C., Jun G., Beecham G. W. et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 43, 436441.
  • Olson M. I. and Shaw C. M. (1969) Presenile dementia and Alzheimer’s disease in mongolism. Brain 92, 147156.
  • Perrin R. J., Fagan A. M. and Holtzman D. M. (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 461, 916922.
  • Poorkaj P., Bird T. D., Wijsman E., Nemens E., Garruto R. M., Anderson L., Andreadis A., Wiederholt W. C., Raskind M. and Schellenberg G. D. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815825.
  • Robakis N. K., Wisniewski H. M., Wisniewski H. M. et al. (1987) Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1, 384385.
  • Rovelet-Lecrux A., Hannequin D., Raux G. et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 2426.
  • Schellenberg G. D., Bird T. D., Wijsman E. M. et al. (1988) Absence of linkage of chromosome 21q21 markers to familial Alzheimer’s disease. Science 241, 15071510.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177.
  • Scheuner D., Eckman C., Jensen M. et al. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864870.
  • Seubert P., Vigo-Pelfrey C., Esch F. et al. (1992) Isolation and quantification of soluble Alzheimer’s beta-peptide in biological fluids. Nature 359, 325329.
  • Sherrington R., Rogaev E. I., Liang Y. et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375, 754760.
  • St George-Hyslop P. H. and Petit A. (2005) Molecular biology and genetics of Alzheimer’s disease. C R Biol. 328, 119130.
  • St George-Hyslop P. H., Tanzi R. E., Polinsky R. J. et al. (1987) The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 235, 885890.
  • St George-Hyslop P. H., Haines J. L., Farrer L. A. et al. (1990) Genetic linkage studies suggest that Alzheimer’s disease is not a single homogenous disorder. Nature 347, 194197.
  • Sturchler-Pierrat C., Abramowski D., Duke M. et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 1328713292.
  • Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. Jr, Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 13361340.
  • Tanzi R. E., Gusella J. F., Watkins P. C., Bruns G. A., St George-Hyslop P., Van Keuren M. L., Patterson D., Pagan S., Kurnit D. M. and Neve R. L. (1987a) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235, 880884.
  • Tanzi R. E., St George-Hyslop P. H., Haines J. L., Polinsky R. J., Nee L., Foncin J. F., Neve R. L., McClatchey A. I., Conneally P. M. and Gusella J. F. (1987b) The genetic defect in familial Alzheimer’s disease is not tightly linked to the amyloid beta-protein gene. Nature 329, 156157.
  • Van Broeckhoven C., Genthe A. M., Vandenberghe A. et al. (1987) Failure of familial Alzheimer’s disease to segregate with the A4-amyloid gene in several European families. Nature 329, 153155.
  • Van Broeckhoven C., Haan J., Bakker E., Hardy J. A., Van Hul W., Wehnert A., Vegter-Van der Vlis M. and Roos R. A. C. (1990) The beta-amyloid precursor protein gene is tightly linked to the locus causing Hereditary Cerebral Hemorrhage with Amyloidosis of Dutch Type. Science 248, 488490.